Compare Bristol-Myers Squibb Co (BMY) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Hilton Hotels Corporation Common Stock — how do they compare? Bristol-Myers Squibb Co trades at $63.88 (market cap $129.94B), while Hilton Hotels Corporation Common Stock trades at $321.95 (market cap $70.82B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | HLT | |
|---|---|---|
Market Cap | $129.94B | $70.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $350.22 |
52-Week Low | $42.60 | $256.75 |
Enterprise Value | $163.92B | $83.83B |
Dividend Yield | 3.96% | 0.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Hilton Worldwide Holdings (HLT) trades at $311.00, down 2.08% over 24 hours, amid a bearish technical signal. The stock shows strong fundamentals with Q2 2026 EPS of $2.29 meeting estimates and revenue growth to $12.04 billion in 2025. However, a high P/E of 46.21 and rising debt-to-asset ratio to 73.88% in 2025 highlight valuation and leverage concerns. Recent news includes a 50-day strike at a Seattle hotel and mixed institutional trading activity.
The outlook for HLT is cautiously optimistic, supported by robust travel demand and a record pipeline, but tempered by premium valuation and debt risks. Analysts maintain a buy consensus with a $352.00 price target, suggesting 13% upside. Key risks include labor disputes, soft international demand, and interest rate sensitivity. Investors should weigh growth prospects against financial leverage and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
